Comparisons of Bleeding Risks between Rivaroxaban and Dalteparin for Treatment of Venous Thromboembolism in Cancer Patients |
Kim, Yoon Kyung
(Graduate School of Clinical Health Sciences, Ewha Womans University)
An, Sook Hee (College of Pharmacy, Wonkang University) Kim, Jae Yeon (Division of Pharmaceutical Services, Asan Medical Center) Chung, Jee Eun (College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University) Gwak, Hye Sun (Graduate School of Clinical Health Sciences, Ewha Womans University) |
1 | Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. J Thromb Haemost 2002;87(4):575-9. DOI |
2 | Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005;6(6):401-10. DOI |
3 | Buller HR, van Doormaal FF, van Sluis GL, et al. Cancer and thrombosis:from molecular mechanisms to clinical presentations. J Thromb Haemost 2007;5(1):246-54. DOI |
4 | Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25(34):5490-505. DOI |
5 | Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6):454S-545S. DOI |
6 | Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005;78(4):412-21. DOI |
7 | Agnelli G, Berkowitz S, Bounameaux H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363(26):2499-510. DOI |
8 | Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366(14):1287-97. DOI |
9 | Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism:a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11(1):21. DOI |
10 | Beyer-Westendorf J, Frster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124(6):955-62. DOI |
11 | Chang HY, Zhou M, Tang W, et al. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 2015;350:h1585. DOI |
12 | Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166(4):458-64. DOI |
13 | Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91. DOI |
14 | Yamada N, Hirayama A, Maeda H, et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism-the J-EINSTEIN DVT and PE program. Thromb J 2015;13(2):b13. DOI |
15 | Lalibert F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014;30(7):1317-25. DOI |
16 | Wasserlauf G, Grandi SM, Filion KB, et al. Meta-analysis of rivaroxaban and bleeding risk. Am J Cardiol 2013;112(3):454-60. DOI |
17 | Cohen AT, Spiro TE, Bller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013;368(6):513-23. DOI |